Trial Profile
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Prednisone
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Acronyms SEMAPHORE
- 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism.
- 03 Jun 2023 Data from this study was used to identify predictive factors of favourable evolution in GC-dependent PMR patients to optimize its management, presented at the 24th Annual Congress of the European League Against Rheumatism.
- 20 Sep 2022 Primary endpoint has been met. (Low disease activity (PMR-AS10) with steroid independence (GCs 5 mg (absolute value) or decrease 10 mg from week 0 to week 24), as per Results published in the JAMA: the Journal of the American Medical Association